Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06822049 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Remote vs. In-Person Study Evaluation (RISE) Trials: RISE Above Smoking (Trial 1)

StatusCompleted
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fields
  2. Primary endpoints: details revised at 2 of 4 entries
    • Trial completed
    • Study completion date changed from estimate of Feb 28, 2027 to Aug 27, 2026
    • Eligibility criteria expanded, about 7 words
  3. Primary completion pushed from Jul 31, 2026 to Aug 31, 2026v9
  4. Trial status changed: Recruiting → Active, Not Recruiting
    • Site details revised at 2 of 2 sites
    v8
  5. Collaborators: 5 to 6v7
Show 5 earlier versionsHide 5 earlier versions
  1. Eligibility criteria expanded, about 59 wordsv6
  2. Re-verified, no change to tracked fieldsv5
  3. Start date: Feb 20, 2025 to Mar 10, 2025v4
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Mar 10, 2025 to Feb 20, 2025
    • Site details revised at 2 of 2 sites
    v3
  5. Start date: Feb 3, 2025 to Mar 10, 2025v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The study will employ a randomized, parallel-group design with two-stage randomization. After an initial brief screen for basic eligibility, participants will be randomized (within site) to either Remote (R) or In-Person (IP) Intake Groups. During the Intake, detailed consent and eligibility assessment will be completed. Participants who are eligible at the Intake will be randomized (within site and Intake Group) to R or IP Treatment and Assessment Groups. Participants will be followed for 3 months.
Trial Details
NCT Number NCT06822049
Lead Sponsor State University of New York at Buffalo
Collaborators: Medical University of South Carolina, University of Pennsylvania, University of Alabama at Birmingham, National Center for Advancing Translational Sciences (NCATS), Abramson Cancer Center at Penn Medicine, Wake Forest University Health Sciences
Conditions
(from sponsor)		 Remote vs. In-Person, Remote Visits, In-person Visits
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov